Fully Liquid Meningococcal Vaccine Approved in Europe

GSK plc today announced that the European Commission (EC) had approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135, and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y.

Philip Dormitzer, GSK Head of Global Vaccines Research & Development, commented in a press release on November 27, 2024, “As a leader in meningococcal vaccines, GSK is dedicated to finding innovative solutions that simplify immunization and support vaccine uptake. We remain committed to safeguarding individuals from bacterial meningitis and will persist in our efforts to prevent this devastating disease among at-risk populations in the European Union.”

IMD is an unpredictable, serious illness that can cause life-threatening complications. Despite treatment, among those who contract IMD, up to one in six will die, sometimes in as little as 24 hours.

One in five survivors may suffer long-term consequences such as neurological damage6, amputations, hearing loss, and nervous system problems.

Although anyone can get IMD, babies, young children, and those who are in their late teens and early adulthood are amongst the groups at higher risk.

This single-vial presentation of Menveo is now licensed for active immunization of children from 2 to adolescents and adults. It offers healthcare providers an option that does not require reconstitution before use. More than 82 million doses of this vaccine have been distributed worldwide since 2010.